Washington, DC
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Reagan-Udall Foundation for the Food and Drug Administration Inc, founded in 2009, is a community nonprofit that reported $8.2M in total revenue in fiscal year 2024. Expenses of $7.9M left a modest 4% surplus.
Advance the mission of the Food and Drug Administration to modernize product development, accelerate innovation, and enhance product safety.
Advancing Regulatory Science- Provide data assets, evaluation tools, and career development opportunities to help FDA assess the risks and benefits of regulated products. Examples include the the...
Advancing Regulatory Science- Provide data assets, evaluation tools, and career development opportunities to help FDA assess the risks and benefits of regulated products. Examples include the the Innovation in Medical Evidence and Development Surveillance (IMEDS) Program, Fellowship in Regulatory Science & Innovation, and the ASH Real-World Evidence Consortium.
Supporting Development and Dissemination of Reliable Information- Improve public understanding of the risks and benefits of FDA-regulated products. Identify priority areas for consumer, patient, and...
Supporting Development and Dissemination of Reliable Information- Improve public understanding of the risks and benefits of FDA-regulated products. Identify priority areas for consumer, patient, and provider education in areas of emerging science. Examples include Expanded Access Navigator, Nutrition Communications Network, Improving Human Health Risk Communication, and Animal Health and Veterinary Industry Analysis.
Facilitating Engagement and Information Exchange - Facilitate multi-stakeholder collaboration to accelerate evidence generation and dissemination. Enable expert analysis, candid discussion, and...
Facilitating Engagement and Information Exchange - Facilitate multi-stakeholder collaboration to accelerate evidence generation and dissemination. Enable expert analysis, candid discussion, and actionable recommendations relevant to the FDA Mission. Examples include Healthy Rule Roundtables, Food Traceability Roundtables, Primary Mitochondrial Diseases Workshop, FDA Patient Listening Sessions, and Biosimilars Development Regulatory Science Accelerator.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $8,241,574 | $8,216,727 | +0.0% |
| Expenses | $7,880,139 | $7,790,276 | +0.0% |
| Net Income | $361,435 | $426,451 | -0.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Richard L Schilsky | Board Chair | 4.00 |
Officer
Director
|
$0 | $0 | $0 |
| Adrian F Hernandez | Board Vice Chair | 4.00 |
Officer
Director
|
$0 | $0 | $0 |
| Debra L Ness | Treasurer | 4.00 |
Officer
Director
|
$0 | $0 | $0 |
| Lynne Zydowsky | Secretary | 4.00 |
Officer
Director
|
$0 | $0 | $0 |
| Edward J Allera | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Christie Boutte | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Phil Febbo | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| David C Fajgenbaum | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| William N Hait | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| James EK Hildreth | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Esther Krofah | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Phuong Khanh PK Morrow | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Richard Moscicki | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Reed V Tuckson | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Pietro Antonio Tataranni | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Andrew C von Eschenbach | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Sumbul Desai | Director | 4.00 |
Director
|
$0 | $0 | $0 |
| Susan C Winckler RPh JD | Chief Executive Officer | 40.00 |
Officer
|
$448,815 | $38,316 | $487,131 |
| Amar Bhat PhD | Chief Operating Officer | 40.00 |
Officer
|
$227,004 | $34,161 | $261,165 |
| Carla Rodriguez-Watson PhD | Director, Research | 40.00 |
Highest
|
$221,228 | $25,657 | $246,885 |
| Lea Ann Browning-McNee MA | Director, Communication and Stakeholder Engagement | 40.00 |
Highest
|
$185,985 | $31,595 | $217,580 |
| David E Woodbury Jr MBA | Director, Operations | 40.00 |
Highest
|
$172,960 | $32,298 | $205,258 |
| Carolyn Hiller | Senior Advisor for Innovation and Strategic Partne | 40.00 |
Highest
|
$164,513 | $31,660 | $196,173 |
| Esther Boadi | Engagement Manager | 40.00 |
Highest
|
$121,425 | $16,216 | $137,641 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $8,241,574 | $7,880,139 | $7,237,733 | $361,435 |
| 2023 | $8,216,727 | $7,790,276 | $6,385,158 | $426,451 |
| 2022 | $8,752,229 | $8,633,422 | $8,144,687 | $118,807 |
| 2021 | $5,435,911 | $5,303,683 | $4,910,430 | $132,228 |
| 2020 | $4,858,127 | $4,442,490 | $5,042,218 | $415,637 |
| 2019 | $2,778,525 | $2,521,247 | $4,065,358 | $257,278 |
| 2018 | $2,433,027 | $1,847,661 | $3,164,298 | $585,366 |
Compare Reagan-Udall Foundation for the Food and Drug Administration Inc with other nonprofits in District of Columbia and across the country.